{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:35:03Z","timestamp":1777253703787,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.autrev.2022.103205","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T03:07:31Z","timestamp":1664766451000},"page":"103205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases"],"prefix":"10.1016","volume":"21","author":[{"given":"Milena","family":"Tocut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ora","family":"Shovman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Boaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Laviel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stav","family":"Debi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Nama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Akria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"Soroksky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele","family":"Zandman-Goddard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103205_bb0005","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.2174\/138161211798157540","article-title":"Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases","volume":"17","author":"Katz","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"652","key":"10.1016\/j.autrev.2022.103205_bb0010","first-page":"e9","article-title":"Intravenous immunoglobulin in critically ill adults: when and what is the evidence?","volume":"30","author":"Wang","year":"2015","journal-title":"J Crit Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0015","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1592\/phco.2005.25.11part2.85S","article-title":"The patient: emerging clinical applications of intravenous immunoglobulin","volume":"25","author":"Harvey","year":"2005","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.autrev.2022.103205_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103205_bb0025","series-title":"Autoimmunity: From Bench to Bedside","article-title":"Intravenous immunoglobulin-customized therapy","author":"Zandman-Goddard","year":"2013"},{"key":"10.1016\/j.autrev.2022.103205_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: Adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103205_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology."},{"key":"10.1016\/j.autrev.2022.103205_bb0040","first-page":"777","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"368","author":"Gelfand","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2014a review of the literature","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103205_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","article-title":"Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases","volume":"42","author":"Zandman-Goddard","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103205_bb0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1177\/0961203309106921","article-title":"Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside","volume":"18","author":"Zandman-Goddard","year":"2009","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2022.103205_bb0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-3148.2010.01022.x","article-title":"Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes","volume":"20","author":"Foster","year":"2010","journal-title":"Transfus Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0065","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1111\/j.1537-2995.2007.01400.x","article-title":"Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group","volume":"47","author":"Constantine","year":"2007","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.autrev.2022.103205_bb0070","first-page":"559","article-title":"Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness","volume":"82","author":"Busani","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.autrev.2022.103205_bb0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jcrc.2015.02.012","article-title":"Intravenous immunoglobulin improves sepsis-induced coagulopathy: a retrospective, single-center observational study","volume":"30","author":"Ishikura","year":"2015","journal-title":"J Crit Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/cc10597","article-title":"Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective","volume":"16","author":"Shankar-Hari","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-010-0800-y","article-title":"Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol","volume":"66","author":"Ruiz-Antor\u00e1n","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2022.103205_bb0090","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/cc7936","article-title":"The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes","volume":"13","author":"Martin","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0095","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00134-018-5047-6","article-title":"Immunoglobulins and sepsis","volume":"44","author":"Shankar-Hari","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/joim.12265","article-title":"GRECIA Group (Grupo de Estudios y An\u00e1lisis en Cuidados Intensivos). Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis","volume":"276","author":"Bermejo-Mart\u00edn","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13613-017-0268-3","article-title":"The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure","volume":"7","author":"Martin-Loeches","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0110","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00134-015-3845-7","article-title":"Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis","volume":"41","author":"Shankar-Hari","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2016.10.057","article-title":"Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction: Insights from a prospective database of ED patients with infection","volume":"151","author":"Williams","year":"2017","journal-title":"Chest."},{"key":"10.1016\/j.autrev.2022.103205_bb0120","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.autrev.2022.103205_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5644\/ama2006-124.165","article-title":"Predictive value of SAPS II and APACHE II scoring systems for patient outcome in a medical intensive care unit","volume":"45","author":"Godinjak","year":"2016","journal-title":"Acta Med Acad"},{"issue":"676","key":"10.1016\/j.autrev.2022.103205_bb0130","first-page":"82","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.autrev.2022.103205_bb0135","doi-asserted-by":"crossref","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","article-title":"Sepsis in intensive care unit patients: Worldwide data from the intensive care over nations audit","volume":"5","author":"Sakr","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.autrev.2022.103205_bb0140","first-page":"2686","article-title":"Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis","volume":"35","author":"Laupland","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","article-title":"Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis","volume":"146","author":"Turgeon","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2016.01.021","article-title":"Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins","volume":"22","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.autrev.2022.103205_bb0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-3083.2005.01568.x","article-title":"The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used","volume":"61","author":"Djoumerska","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2022.103205_bb0160","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/rheumatology\/keq021","article-title":"The role of high-dose intravenous immunoglobulin in rheumatology","volume":"49","author":"Vaitla","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103205_bb0165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1503\/cmaj.130375","article-title":"Intravenous immunoglobulin as clinical immune-modulating therapy","volume":"187","author":"Gilardin","year":"2015","journal-title":"CMAJ."},{"key":"10.1016\/j.autrev.2022.103205_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.23736\/S0375-9393.18.13349-9","article-title":"Intravenous immunoglobulin in sepsis: can we find the right dose?","volume":"85","author":"Szakmany","year":"2019","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.autrev.2022.103205_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcrc.2011.05.012","article-title":"Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis","volume":"27","author":"Berlot","year":"2012","journal-title":"J Crit Care"},{"key":"10.1016\/j.autrev.2022.103205_bb0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.23736\/S0375-9393.18.12344-3","article-title":"Single versus divided administration of intravenous immunoglobulin for sepsis: A retrospective and historical control study","volume":"85","author":"Nakamura","year":"2019","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.autrev.2022.103205_bb0185","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","article-title":"Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: A randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)","volume":"44","author":"Welte","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00134-005-2563-y","article-title":"Prognosis of patients with systemic rheumatic diseases admitted to the intensive care unit","volume":"31","author":"Moreels","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0195","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/rheumatology\/keg322","article-title":"Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit","volume":"42","author":"Cruz","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103205_bb0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/RHU.0b013e3181ffe517","article-title":"Outcome of patients with systemic rheumatic diseases admitted to a medical intensive care unit","volume":"16","author":"Cavallasca","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103205_bb0205","first-page":"1317","article-title":"Short and longterm outcomes for patients with systemic rheumatic diseases admitted to intensive care units: a prognostic study of 181 patients","volume":"24","author":"Godeau","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103205_bb0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1191\/0961203305lu2082oa","article-title":"Autoimmune rheumatic diseases in the intensive care unit: experience from a tertiary referral hospital and review of the literature","volume":"14","author":"Camargo","year":"2005","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2022.103205_bb0215","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.autrev.2012.06.002","article-title":"Autoimmune diseases in the intensive care unit. An update","volume":"12","author":"Quintero","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103205_bb0220","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0749-0704(02)00025-8","article-title":"Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome","volume":"18","author":"Janssen","year":"2002","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.autrev.2022.103205_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000122","article-title":"Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis","volume":"2","author":"Bernal-Mac\u00edas","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2022.103205_bb0230","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.berh.2019.01.013","article-title":"Mortality of patients with systemic lupus erythematosus admitted to the intensive care unit - A retrospective single-center study","volume":"32","author":"Zamir","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:47Z","timestamp":1761600467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1568997222001756"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103205","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103205"}}